Skip to content

Trials Comparing of HD Versus 4K Laparoscopy for Gastric Cancer

Randomized Controlled Trials Comparing Clinical Outcome of HD Versus 4K Laparoscopy for Gastric Cancer(FUGES-017)

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04010006
Enrollment
502
Registered
2019-07-08
Start date
2019-07-15
Completion date
2023-07-15
Last updated
2020-01-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stomach Neoplasms

Keywords

Stomach Neoplasms, Laparoscopy

Brief summary

The purpose of this study is to explore the feasibility of 4K Laparoscopic Surgery for Gastric Cancer.

Detailed description

A prospective randomized comparison of HD and 4K laparoscopic surgery for gastric cancer will be performed, to evaluate the clinical value and provide theoretical basis and clinical experience for the extensive application of the 4K laparoscopic technique. The evaluation parameters are perioperative clinical efficacy, postoperative life quality, immune function and 3-year survival and recurrence rates.

Interventions

PROCEDURE4K Laparoscopic Surgery

4K Laparoscopic Surgery will be performed for the treatment of patients assigned to this group.

PROCEDUREHD Laparoscopic Surgery

HD Laparoscopic Surgery will be performed for the treatment of patients assigned to this group.

Sponsors

Fujian Medical University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
19 Years to 74 Years
Healthy volunteers
No

Inclusion criteria

* (1)Age from over 19 to under 74 years * (2)cT 1-4a(clinical stage tumor), N0-3, M0 at preoperative evaluation according to the American Joint Committee on Cancer (AJCC) Cancer Staging Manual Seventh Edition * (3)Heart, lungs, kidneys and other vital organs function well, with no obvious surgical contraindications * (4)Preoperative examination with no distant metastasis, no significantly enlarged lymph nodes around abdominal main artery, and tumor not a direct violation of the pancreas, spleen and other surrounding organs * (5)American Society of Anesthesiology (ASA) score class I, II, or III * (6)Written informed consent

Exclusion criteria

* (1)Women during pregnancy or breast-feeding * (2)Severe mental disorder * (3)History of previous upper abdominal surgery (except laparoscopic cholecystectomy) * (4)Enlarged splenic hilar lymph nodes with integration into a mass and surrounding the blood vessels * (5)History of unstable angina or myocardial infarction within past six months * (6)History of cerebrovascular accident within past six months * (7)History of continuous systematic administration of corticosteroids within one month * (8)History of previous neoadjuvant chemotherapy or radiotherapy * (9)T4b tumors * (10)Emergency surgery due to complication (bleeding, obstruction or perforation) caused by gastric cancer * (11)FEV1(Forced expiratory volume in one second)#50% of predicted values

Design outcomes

Primary

MeasureTime frameDescription
operating time1 dayday

Secondary

MeasureTime frameDescription
the number of positive lymph nodes1 daythe number of positive lymph nodes
intraoperative lymph node dissection time1 day(regional analysis:infrapyloric area lymph node,suprapancreatic area lymph node,splenic hilar area lymph node,cardial area lymph node)
intracavitary anastomosis time1 day(patients who undergo totally laparoscopic surgery are analyzed)
intraoperative blood loss1 dayml
intraoperative injury1 dayintraoperative injury
the amount of use of titanium clip1 daythe amount of use of titanium clip
the rate of conversion to laparotomy1 daythe rate of conversion to laparotomy
Time to first ambulation10 daysTime to first ambulation
Time to first flatus10 daysTime to first flatus
The number of lymph node dissection1 daynumber
Time to first soft diet10 daysTime to first soft diet
duration of postoperative hospital stay10 daysduration of postoperative hospital stay
Complication30 days;36 months(early complications occurred within 30 days after operation): pulmonary infection, incision complication, intestinal obstruction, abdominal infection, anastomotic bleeding, anastomotic fistula, gastric emptying; long term complications (30 days later after operation): anastomotic stenosis, intestinal obstruction, dumping syndrome
The daily highest body temperature before discharge7 daysThe daily highest body temperature before discharge
Overall postoperative morbidity and mortality rates30 daysThe number of all patients treated with surgery as the denominator and the number of the patients with any intraoperative and postoperative morbidity and mortality as the numerator are used to calculate the proportions. Postoperative morbidities are divided into short-term and long-term complications after surgery. Short-term is defined as within 30 days of surgery or the first discharge if the hospital stay is \> 30 days. Long-term is defined as the period from 30 days or more after the operation or the period between first discharge (the hospital days after surgery \>30 days) and 3 years after the operation. Postoperative mortality: patients whose death was identified according to documented intraoperative observation items, including patients who die within 30 days after surgery (including the 30th day) regardless of the causality between death and surgery, and patients who die more than 30 days after surgery.
Hospitalization expenses1 monthsdolloars
3-year disease free survival rate36 monthsmonth
3-year overall survival rate36 monthsmonth
Time to first liquid diet10 daysTime to first liquid diet

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026